Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC)
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …

Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and
robust therapeutic potential in clinical practice. It can significantly improve progression-free …

Distant metastasis remains the major cause of morbidity for breast cancer. Individuals with
liver or brain metastasis have an extremely poor prognosis and low response rates to anti …

ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have recently entered into the
therapeutic scenario of metastatic breast cancer. However, only a proportion of patients …

How tumor cells genetically lose antigenicity and evade immune checkpoints remains
largely elusive. We report that tissue-specific expression of the human long noncoding RNA …

Breast cancer accounts for 25% of all types of cancer in women, and triple negative breast
cancer (TNBC) comprises around 15~ 20% of breast cancers. Conventional chemotherapy …

Introduction Immune checkpoint inhibitor (ICI) monotherapy appears to be effective in a
small cohort of patients with metastatic triple negative breast cancer (mTNBC). This supports …

Heterogeneity of triple-negative breast cancer is well known at clinical, histopathological,
and molecular levels. Genomic instability and greater mutation rates, which may result in the …

Triple-negative breast cancer (TNBC) is known as the most intricate and hard-to-treat
subtype of breast cancer. TNBC cells do not express the well-known estrogen receptor …

Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, but
an effective targeted therapy has not been well-established so far. Considering the lack of …